JAK Inhibitor Dermatology Deal Benchmarks

Median Upfront

$370M

Range: $202M - $532M

Total Deal Value

$2.0B

Range: $1.3B - $2.7B

Royalty Rate

6.4% - 12.9%

Tiered up to 16.9%

Dev Milestones

$329M

Range: $221M - $437M

Model Your Deal

Market Analysis

JAK inhibitors have expanded from rheumatology into dermatology, with baricitinib (AD), upadacitinib (AD), abrocitinib (AD), and ritlecitinib (alopecia areata) establishing the oral immunodermatology class. Phase 2 JAK inhibitor deals in dermatology carry a median total deal value of $2.0B, with upfront payments of $370M. The oral convenience advantage over injectable biologics drives strong patient preference and payer interest.

Deal structures reflect the balance between the proven anti-inflammatory mechanism and the ongoing safety scrutiny from FDA boxed warnings on JAK inhibitors. Development milestones average $329M, with gating criteria often tied to long-term safety data in addition to efficacy endpoints. Regulatory milestones of $411M and commercial milestones of $904M reward successful market entry.

Royalty rates for dermatology JAK inhibitor deals range from 6.4% to 12.9%. Next-generation selective JAK1 or TYK2 inhibitors with improved cardiovascular and thromboembolic safety profiles command premium terms. Topical JAK inhibitors (ruxolitinib cream for AD, vitiligo) represent a differentiated approach that avoids systemic exposure concerns while maintaining JAK pathway efficacy.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for dermatology JAK inhibitors?

Phase 2 dermatology JAK inhibitor deals average $370M upfront with $2.0B total deal value. Selective JAK1 inhibitors with clean safety profiles command the highest deal premiums in the class.

How do JAK safety concerns affect deal valuations?

FDA boxed warnings on JAK inhibitors (MACE, VTE, malignancy, infections) have moderated deal premiums compared to pre-2022 levels. However, next-generation selective inhibitors (JAK1-only, TYK2) with improved safety data are recovering deal value. Long-term safety data is now a critical milestone gate in JAK inhibitor deals.

How do topical vs. oral JAK inhibitor deals compare?

Topical JAK inhibitors command similar total deal values to oral formulations despite lower per-patient revenue, because they avoid systemic safety concerns and can access broader patient populations. Ruxolitinib cream for AD and vitiligo has demonstrated the commercial viability of the topical approach.

Which dermatology indications are most targeted by JAK inhibitor deals?

Atopic dermatitis leads in deal volume, followed by alopecia areata, vitiligo, hidradenitis suppurativa, and prurigo nodularis. The oral convenience and broad anti-inflammatory mechanism of JAK inhibitors make them attractive across multiple inflammatory dermatoses.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

JAK Inhibitor Dermatology Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Dermatology Deal Overview

IL-17 Inhibitor Deals

Small Molecule Deals

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?